SNN

Smith & Nephew plc: 2001 Annual Report (Form 20-F) Summary

Business Context and Reporting Period

Company: Smith & Nephew plc
Reporting Period: Fiscal year ended December 31, 2001
Accounting Basis: UK GAAP (with US GAAP reconciliations provided)
Business Overview: A global medical device company focused on orthopaedics, endoscopy, and advanced wound management. The company underwent significant strategic restructuring in 2001, including the formation of a 50/50 joint venture (BSN Medical) with Beiersdorf AG for its traditional woundcare and casting businesses, and the disposal of its ear, nose, and throat business.

Key Financial Metrics (UK GAAP)

Note: Adjusted EPS excludes exceptional items and gains/losses on disposals to reflect underlying performance.

Material Changes vs. Prior Period

• Revenue Decline: Total group turnover decreased by 5% to GBP 1,081.7 million. However, Ongoing Operations (core growth businesses) grew by 21% (13% underlying growth, 6% from acquisitions, 2% currency).
• Profitability: Reported profit for the year fell 37% to GBP 129.6 million, primarily due to the absence of the GBP 109.5 million gain on the disposal of the consumer healthcare business in 2000. Conversely, Adjusted Profit Before Tax was relatively flat (GBP 170.5 million vs. GBP 172.0 million in 2000).
• Segment Performance:
  • Orthopaedics: Sales grew 21% to GBP 398.8 million.
  • Endoscopy: Sales grew 17% to GBP 252.8 million.
  • Advanced Wound Management: Sales grew 29% to GBP 285.6 million.
• Disposals: The ear, nose, and throat business was sold in June 2001 for a net cash consideration of GBP 61.7 million, resulting in a net gain of GBP 49.2 million.
• Joint Venture: Traditional woundcare and casting businesses were contributed to BSN Medical on April 1, 2001. Results prior to this date are reported as "Operations contributed to the joint venture."

Guidance, Outlook, and Risks

• Strategic Outlook: Management expects continued growth in core segments driven by an aging population and demand for minimally invasive procedures. The company plans to invest in R&D (5% of sales) and acquisitions.
• Recent Acquisitions: In March 2002 (post-year-end), the company acquired ORATEC Interventions, Inc. for net $258 million to expand its endoscopy portfolio. This was funded by new committed bank facilities.
• Dividend Policy: The Board raised the dividend cover to 2.7 times in 2001 to retain cash for growth. A final dividend of 2.9p per share was approved.
• Key Risks:
  • Currency: Significant exposure to exchange rate fluctuations, particularly between Sterling and the US Dollar. A 10% weakening of Sterling would have increased 2001 pre-tax profit by GBP 21 million.
  • Regulatory: Dependence on FDA and other regulatory approvals for new products.
  • Product Liability: Inherent risks in the medical device industry, though management believes insurance coverage is adequate.
  • Integration: Risks associated with integrating acquired businesses and the new joint venture.

Investor Verification Checklist

• US GAAP Reconciliation: Verify the impact of US GAAP adjustments on Net Income (US GAAP Net Income was GBP 108.5 million vs. UK GAAP GBP 129.6 million) and Shareholders' Equity.
• Exceptional Items: Review the GBP 21.1 million of exceptional costs charged in 2001 (rationalization and integration) to assess the true operating margin of ongoing businesses.
• Net Debt Position: Confirm the increase in net borrowings to GBP 243.5 million and the adequacy of committed bank facilities (GBP 323 million) to support the ORATEC acquisition.
• Joint Venture Accounting: Understand the "gross equity method" used for BSN Medical and the specific share of operating profit (GBP 12.8 million) included in 2001 results.
• Pension Obligations: Review Note 26 regarding the funding status of defined benefit pension plans, which showed a surplus under UK GAAP but would show a net liability of GBP 24.5 million under FRS 17.